Despite the promising results of cemiplimab and pembrolizumab use in treating patients with advanced unresectable or metastatic cSCC, the role of the PD-1:PD-L1/PD-L2 axis in cSCC had not been well elucidated. The gene discussed is PDCD1LG2; the disease is skin squamous cell carcinoma.